Hold Strides Shasun, says Shahina Mukadam

Shahina Mukadam, Independent Market Expert told CNBC-TV18, "One should hold Strides Shasun. There are couple of issues. The stock had corrected because there is short-term issue regarding its sell of plant to Mylan for which there is likely to be some demand and the company has already provided USD 200 million on the same front, which is why the stock had corrected."She further added, "On the other hand, the stock has done its qualitative institutional placement (QIP). It has raised over Rs 1,000 crore. So now it is sitting on a reasonable cash balance, so it should not be a major issue meeting its liabilities. In terms of overall valuation if you see, it is pretty attractive just about 10-12 times multiple one year forward earnings, which is pretty cheap compared to the other pharmaceutical companies. So I think given the overall business growth with its merger that it has done in the recent past with Shasun, overall business should improve going forward.""If one would like to protect the capital, can put a stoploss of Rs 1,250 and hold it benefit from the run from hereon. Maybe another Rs 100 from here is something one can look out to book around Rs 1,350 to Rs 1,400," she said.